Hafnium Oxide-containing Nanoparticles NBTXR3
Sponsors
M.D. Anderson Cancer Center
Conditions
Advanced Malignant Solid NeoplasmBorderline Resectable Pancreatic AdenocarcinomaCervical Esophagus AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Gastroesophageal Junction Adenocarcinoma
Phase 1
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
SuspendedNCT04484909
Start: 2020-07-01End: 2026-12-31Target: 24Updated: 2026-03-20
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
Active, not recruitingNCT04505267
Start: 2021-02-10End: 2026-03-31Updated: 2026-03-11
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
RecruitingNCT04615013
Start: 2020-11-23End: 2027-10-31Target: 24Updated: 2025-10-30
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RecruitingNCT05039632
Start: 2023-05-08End: 2028-02-01Target: 40Updated: 2026-02-06
Phase 2
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
WithdrawnNCT04834349
Start: 2021-03-09End: 2022-11-21Updated: 2023-09-13
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
TerminatedNCT04862455
Start: 2021-04-07End: 2026-01-21Updated: 2026-01-23